ELIAS Animal Health

About ELIAS Animal Health

ELIAS Animal Health develops ELIAS Cancer Immunotherapy (ECI®), a first-in-class adoptive cell therapy that utilizes a dog's own activated T cells to target and eliminate cancer cells, particularly in cases of bone cancer. This personalized treatment addresses the high incidence of cancer in dogs, providing a viable alternative to traditional chemotherapy and radiation therapies.

```xml <problem> Cancer is a leading cause of death in dogs, often diagnosed in late stages when treatment options are limited. Traditional cancer treatments like chemotherapy and radiation can have significant side effects, impacting the pet's quality of life. There is a need for more effective and less invasive cancer therapies for canines. </problem> <solution> ELIAS Animal Health offers ELIAS Cancer Immunotherapy (ECI®), an autologous adoptive cell therapy that utilizes a dog's own immune system to target and eliminate cancer cells. The treatment involves vaccinating the dog with its own cancer cells to stimulate an immune response. T cells are then collected via apheresis, activated ex vivo to create a large population of killer T cells, and reinfused into the patient. This personalized approach aims to prolong the dog's life and improve its quality of life by leveraging the power of its own immune system. </solution> <features> - Autologous adoptive cell therapy using the patient's own T cells - Ex vivo T cell activation to enhance cancer-killing capabilities - Personalized vaccine derived from the patient's own cancer cells - Treatment protocol designed to minimize the need for chemotherapy or radiation - Demonstrated effectiveness in multiple rodent and human cancers </features> <target_audience> The primary target audience includes veterinarians and pet owners seeking alternative cancer treatment options for dogs, particularly those looking for therapies that improve quality of life and prolong survival. </target_audience> ```

What does ELIAS Animal Health do?

ELIAS Animal Health develops ELIAS Cancer Immunotherapy (ECI®), a first-in-class adoptive cell therapy that utilizes a dog's own activated T cells to target and eliminate cancer cells, particularly in cases of bone cancer. This personalized treatment addresses the high incidence of cancer in dogs, providing a viable alternative to traditional chemotherapy and radiation therapies.

Where is ELIAS Animal Health located?

ELIAS Animal Health is based in Olathe, United States.

When was ELIAS Animal Health founded?

ELIAS Animal Health was founded in 2014.

Location
Olathe, United States
Founded
2014
Employees
11 employees
Major Investors
Morris Animal Foundation

Find Investable Startups and Competitors

Search thousands of startups using natural language

ELIAS Animal Health

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ELIAS Animal Health develops ELIAS Cancer Immunotherapy (ECI®), a first-in-class adoptive cell therapy that utilizes a dog's own activated T cells to target and eliminate cancer cells, particularly in cases of bone cancer. This personalized treatment addresses the high incidence of cancer in dogs, providing a viable alternative to traditional chemotherapy and radiation therapies.

eliasanimalhealth.com1K+
cb
Crunchbase
Founded 2014Olathe, United States

Funding

Major Investors

Morris Animal Foundation

Team (10+)

No team information available.

Company Description

Problem

Cancer is a leading cause of death in dogs, often diagnosed in late stages when treatment options are limited. Traditional cancer treatments like chemotherapy and radiation can have significant side effects, impacting the pet's quality of life. There is a need for more effective and less invasive cancer therapies for canines.

Solution

ELIAS Animal Health offers ELIAS Cancer Immunotherapy (ECI®), an autologous adoptive cell therapy that utilizes a dog's own immune system to target and eliminate cancer cells. The treatment involves vaccinating the dog with its own cancer cells to stimulate an immune response. T cells are then collected via apheresis, activated ex vivo to create a large population of killer T cells, and reinfused into the patient. This personalized approach aims to prolong the dog's life and improve its quality of life by leveraging the power of its own immune system.

Features

Autologous adoptive cell therapy using the patient's own T cells

Ex vivo T cell activation to enhance cancer-killing capabilities

Personalized vaccine derived from the patient's own cancer cells

Treatment protocol designed to minimize the need for chemotherapy or radiation

Demonstrated effectiveness in multiple rodent and human cancers

Target Audience

The primary target audience includes veterinarians and pet owners seeking alternative cancer treatment options for dogs, particularly those looking for therapies that improve quality of life and prolong survival.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.